Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Aug 18, 2026	S	45,090	$0.38	D	1,411,974	I	By 5AM Ventures II, L.P.
Common Stock^F1,F3	Aug 18, 2026	S	1,830	$0.38	D	55,663	I	By 5AM Co-Investors II, L.P.
Common Stock^F1,F4	Aug 18, 2026	S	253,080	$0.38	D	7,914,126	I	By 5AM Ventures VII, L.P.
Common Stock^F5,F2	Aug 19, 2026	S	10,255	$0.35	D	1,401,719	I	By 5AM Ventures II, L.P.
Common Stock^F5,F3	Aug 19, 2026	S	409	$0.35	D	55,254	I	By 5AM Co-Investors II, L.P.
Common Stock^F5,F4	Aug 19, 2026	S	57,476	$0.35	D	7,856,650	I	By 5AM Ventures VII, L.P.
Common Stock^F2	Aug 20, 2026	S	1,159	$0.32	D	1,400,560	I	By 5AM Ventures II, L.P.
Common Stock^F3	Aug 20, 2026	S	46	$0.32	D	55,208	I	By 5AM Co-Investors II, L.P.
Common Stock^F4	Aug 20, 2026	S	6,495	$0.32	D	7,850,155	I	By 5AM Ventures VII, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
F3The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
F4The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.